Relmada Therapeutics (NASDAQ:RLMD) shares have surged 115% over the past week, fueled by significant insider buying from CEO Sergio Traversa and Chief Medical Officer Raj S. Pruthi. Traversa's purchase of 265,976 shares, bringing his direct ownership to 1 million, underscores his conviction that the biotech is significantly undervalued, which has subsequently ignited a substantial increase in trading volume and renewed investor interest.
Relmada Therapeutics (NASDAQ:RLMD), a small-cap biotech firm, has experienced a significant catalyst-driven rally following substantial insider stock purchases. The buying activity was led by CEO Sergio Traversa, who acquired 265,976 shares to increase his total holdings to 1,000,000 shares, and the Chief Medical Officer, who purchased 55,000 shares. This insider buying has been interpreted by the market as a high-conviction signal, precipitating a 115% increase in the stock price from $0.67 to $1.44 in the past week. The CEO publicly reinforced this signal, stating his belief that the company is "significantly undervalued" and expressing extreme confidence in its pipeline and long-term growth. The market's reaction has been pronounced, with average daily trading volume surging from 650,000 to over 8.25 million shares, indicating a dramatic influx of investor interest directly tied to the executive's actions and statements.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.85
Ticker Sentiment
